Navigation Links
Global Health Progress Initiative Commemorates World Malaria Day
Date:4/25/2008

Research-based biopharmaceutical companies work in partnership with others to fight the malaria epidemic

WASHINGTON, April 25 /PRNewswire-USNewswire/ -- Despite being preventable and treatable, malaria continues to devastate communities in tropical regions throughout Latin America, Asia and Africa. According to the World Health Organization (WHO), the malaria epidemic causes debilitating disease in more than 500 million people worldwide and kills more than one million people each year - mostly infants, young children and pregnant women.

Global Health Progress, an initiative sponsored by the research-based biopharmaceutical companies of EFPIA, IFPMA, PhRMA and Rx&D, joins the global community in commemorating World Malaria Day on April 25. Research-based biopharmaceutical companies are committed to curbing the spread of malaria by working in partnership with governments, NGOs and others to provide education and treatment, and conduct research and development for new drugs and vaccines.

Research-based biopharmaceutical companies collaborate with initiatives such as Roll Back Malaria, the PATH Malaria Vaccine Initiative and the Medicines for Malaria Venture to accelerate the discovery of new medicines, vaccines, diagnostics and other health products to fight malaria. According to a study by the Malaria R&D Alliance, research-based biopharmaceutical and biotech companies fund 36 percent of all new R&D into products to combat malaria.

According to WHO, approximately 40 percent of the world's population are at risk for contracting malaria and, in Africa, malaria causes one in five childhood deaths. Around the world, research-based biopharmaceutical companies are actively engaged in combating malaria through partnerships to improve access to malaria treatments and interventions.

As of 2 November 2007, the R&D industry was conducting research on 24 new medicines and four candidate vaccines for malaria. This includes eight
'/>"/>

SOURCE Global Health Progress
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)... WASHINGTON, Aug. 29 /PRNewswire-USNewswire/ -- Th...onsistent procedures to allow the public to,see ex...ished today in the,Federal Register http://edocke...will ensure that the best and latest available evi... risk assessments for health,standards regulating ...
(Date:8/29/2008)...iation may have caused chromosomal change that rai... FRIDAY, Aug. 29 (HealthDay News) -- Some Japanese...in Hiroshima and Nagasaki experienced key genetic ...of thyroid cancer, new research indicates. , Pa...o a particular genetic mutation involving the so-c...
(Date:8/29/2008)... LEEDS, England, August 29 /PRNewswire/ --, - MYA...ce for Recent,Big Brother Stars but the big Questi...as, mirrors all around and being on national,telev...ct on how you feel,about the way you look. For man... a reality. Upon leaving the house contestants may...
(Date:8/29/2008)... Dr. Milton Owens and the Co... Southern California to provide protection for cas...on, and the Hispanic community is benefiting. , ...ust 29, 2008 -- Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin...
Breaking Medicine News(10 mins):Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2
... to a survey, mental health wards have been graded... mental health inpatients//. The charity called M...ction over the state of repair of their ward while...ndards of hygiene.Mind is for patients to be treat...
... a voluntary organization helping with the necessi...C), Thiruvananthapuram//. To mark its tenth anniv...ir on Wednesday. He handed over a copy of the souv...n.Mr. Bhatia, who applauded the services provided ...
...ients with schizophrenia whose medication is chang...cts, second-generation// antipsychotic drugs do no... first-generation antipsychotic drugs, according t...ves of General Psychiatry, one of the JAMA/Archive...
...has moles. Most of the time, they are nothing but ...ng cells in moles called melanocytes// start divid...r called melanoma. About one in 65 Americans born ...oma at some point during their lifetime. Scientist...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:A decade of service to cancer patients 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3
(Date:8/26/2008)...e/ -- Omeros Corporation today announced the,publi... investigating,OMS103HP in arthroscopic anterior c...103HP is an investigational drug product that is a...signed to improve postoperative,knee function and ...ts an,earlier return to work. The article titled "...
(Date:8/25/2008)...n and Treatment Strategies--, PHILADELPHIA, Aug. ...overed gene mutations that are the main cause of t...blastoma. In addition, the researchers found,that ...-risk forms of,non-inherited neuroblastoma, the mo...nables us to offer the first genetic tests to fami...
(Date:8/25/2008)... calls it a ,miracle, LATHAM, N.Y., Aug. 25 /PRN...ided Radiation Therapy program at Community Care P... patients using RapidArc(TM),radiotherapy technolo...dvancement that delivers a highly-precise image-gu...tment in two minutes or less., RapidArc treatment...
(Date:8/25/2008)...etreatment and Japanese Development Studies ...mark, August 25 /- Genmab h...umab in chronic lymphocytic,leukemia and non-Hodgk...oday plans to begin four studies of,ofatumumab in ...non-Hodgkin,s lymphoma (NHL) this year., "Genmab ...
Breaking Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Thermage and Reliant Technologies to Join Forces 23310 1Thermage and Reliant Technologies to Join Forces 23310 2Thermage and Reliant Technologies to Join Forces 23310 3Thermage and Reliant Technologies to Join Forces 23310 4Thermage and Reliant Technologies to Join Forces 23310 5Thermage and Reliant Technologies to Join Forces 23310 6Thermage and Reliant Technologies to Join Forces 23310 7Angiotech to Establish Separate Operating and Royalty Businesses 6386 1Angiotech to Establish Separate Operating and Royalty Businesses 6386 2Angiotech to Establish Separate Operating and Royalty Businesses 6386 3Angiotech to Establish Separate Operating and Royalty Businesses 6386 4Angiotech to Establish Separate Operating and Royalty Businesses 6386 5Angiotech to Establish Separate Operating and Royalty Businesses 6386 6Angiotech to Establish Separate Operating and Royalty Businesses 6386 7Angiotech to Establish Separate Operating and Royalty Businesses 6386 8Angiotech to Establish Separate Operating and Royalty Businesses 6386 9Angiotech to Establish Separate Operating and Royalty Businesses 6386 10Angiotech to Establish Separate Operating and Royalty Businesses 6386 11Angiotech to Establish Separate Operating and Royalty Businesses 6386 12Angiotech to Establish Separate Operating and Royalty Businesses 6386 13Angiotech to Establish Separate Operating and Royalty Businesses 6386 14Edison Pharmaceuticals Receives Commendation From the City of San Jose 6382 1Edison Pharmaceuticals Receives Commendation From the City of San Jose 6382 2Newborn vitamin A reduces infant mortality 3904 1Newborn vitamin A reduces infant mortality 3904 2
...(CCNMatthews - June 14, 2007) - Ambrilia,Biopharma...oping,novel small molecules and peptides to treat ...neral and Special Meeting today, during,which the ...,integrase inhibitors and recent developments were...hairman of the Board, Mr. Frederic,Porte, and a pr...
...atient Trial Show Those Treated with Lumiracoxib,E...ressure Compared,to Ibuprofen, EAST HANOVER, N.J.,...arthritis who also have controlled hypertension ex... pressure when treated with,the investigational se...slight increase in those taking ibuprofen, a commo...
Other Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5
...nse Webster is the source for a complete line of d...mapping - all with the quality, reliability and pr...eader in catheter technology. All of our coronary ...tructed to help minimize the frustration and exces...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes).
Mennen Medical offers patient monitoring products for hospital based settings requiring high acuity and medium acuity monitoring. The Envoy patient monitor is Mennens premier monitoring product. The
...IS PhysioLog Hemodynamic Monitoring and Data Manag...m for the cath lab, integrating complete functiona...m analysis , Data collection , Inventory contr... , Procedural reporting ,Data collection ...
Medicine Products: